The Joint
The Joint's revenue rose 5.2% to $55 million in fiscal 2025. Its operating margin was −1.7%, up from −3.6% a year earlier. Free cash flow was $0 million, down 95.9%. It paid out $11 million in dividends and buybacks, 3380% of free cash flow. The diluted share count rose 0.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2018 to 2025, earnings per share grew 52.3% a year and net income 61.8% a year, as new shares raised the share count by 9% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 20 | 10 | 18 | 25 | 24 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 88.4x | −26.5x | 1.8x | −27.2x | −18.0x |
| Current ratio | 1.2x | 0.8x | 1.3x | 1.5x | 1.6x |
| Quick ratio | 1.2x | 0.8x | 1.3x | 1.5x | 1.6x |
Cash flow
Projections
Project The Joint's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What The Joint says to expect
- Full year 2026: system-wide sales
System-wide sales are now expected to be between $508 million and $512 million as compared to the prior range of $519 million to $552 million.
- Full year 2026: adjusted EBITDA
Consolidated Adjusted EBITDA is unchanged and is expected to be in the range of $12.5 million to $13.5 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $2.4 million of The Joint shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | Charles E Jobson10% owner | Bought | 44,963 | $6.65 | $299,004 | Form 4 |
| Nov 18, 2026 | Charles E Jobson10% owner | Bought | 10,396 | $6.65 | $69,133 | Form 4 |
| Nov 17, 2026 | Charles E Jobson10% owner | Bought | 1,614 | $6.65 | $10,733 | Form 4 |
| Nov 16, 2026 | Charles E Jobson10% owner | Bought | 1,483 | $6.65 | $9,862 | Form 4 |
| May 13, 2026 | Charles E Jobson10% owner | Bought | 20,375 | $8.57 | $174,614 | Form 4 |
| May 12, 2026 | Charles E Jobson10% owner | Bought | 127,676 | $8.57 | $1.1 million | Form 4 |
| Apr 21, 2026 | Charles E Jobson10% owner | Bought | 509 | $8.58 | $4,367 | Form 4 |
| Feb 12, 2026 | Charles E Jobson10% owner | Bought | 15,397 | $8.50 | $130,874 | Form 4 |
| Feb 11, 2026 | Charles E Jobson10% owner | Bought | 448 | $8.70 | $3,898 | Form 4 |
| Jan 26, 2026 | Charles E Jobson10% owner | Bought | 725 | $10.00 | $7,250 | Form 4 |
| Jan 23, 2026 | Charles E Jobson10% owner | Bought | 16,753 | $10.00 | $167,530 | Form 4 |
| Jan 6, 2026 | Charles E Jobson10% owner | Bought | 5,240 | $8.89 | $46,584 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 24.5% | −39.9% | 5.8% |
| Altman Z'' | 0.43 | 1.12 | 0.99 |
| Accruals ratio | −27.0% | −17.9% | 1.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put The Joint side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| The Joint | FY25 | 5.2% | −1.7% | 0.6% | — | — | — | |
| Sonida Senior Living | FY25 | 25.2% | — | −2.3% | −3.8% | 29.2x | 3 | Compare |
| U.S. Physical Therapy | FY25 | 16.3% | 11.1% | 7.8% | 10.7% | 1.2x | 6 | Compare |
| Nutex Health | FY25 | 82.4% | 31.5% | 28.1% | 40.3% | 0.5x | 7 | Compare |
| National Healthcare | FY25 | 16.1% | 8.5% | 9.8% | 9.4% | −0.3x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 20 | 25 | 37 | 48 | 59 | 80 | 101 | 118 | 52 | 55 |
| Revenue growth | 48.3% | 21.4% | 47.1% | 32.2% | 21.1% | 36.3% | 26.6% | 16.2% | −55.7% | 5.2% |
| Gross profit | 18 | 22 | 32 | 43 | 52 | 72 | 90 | 107 | 41 | 44 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | −15 | −3 | 0 | 3 | 6 | 6 | −2 | 0 | −2 | −1 |
| Net income | −15 | −3 | 0 | 3 | 13 | 8 | 1 | −10 | −6 | 3 |
| Diluted EPS (US$) | −1.20 | −0.26 | 0.01 | 0.23 | 0.90 | 0.51 | −0.38 | −0.65 | −0.38 | 0.19 |
| Diluted shares (millions) | 13 | 13 | 14 | 14 | 15 | 15 | 15 | 15 | 15 | 15 |
| Cash flow | ||||||||||
| Cash from operations | −11 | −0 | 6 | 8 | 11 | 14 | 8 | 15 | 9 | 2 |
| Capital expenditure | 2 | 0 | 1 | 4 | 3 | 7 | 6 | 5 | 1 | 2 |
| Free cash flow | −12 | −1 | 4 | 4 | 8 | 7 | 2 | 10 | 8 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 11 |
| Acquisitions | 1 | 0 | 0 | 3 | 0 | 6 | 0 | 1 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 3 | 4 | 9 | 8 | 21 | 20 | 10 | 18 | 25 | 24 |
| Debt incl. finance leases | 0 | 0 | — | — | — | — | — | — | — | — |
| Total assets | 17 | 18 | 23 | 44 | 66 | 87 | 94 | 87 | 83 | 61 |
| Total liabilities | 10 | 17 | 23 | 38 | 45 | 57 | 61 | 62 | 62 | 46 |
| Shareholders' equity | 7 | 1 | 1 | 6 | 21 | 30 | 33 | 25 | 21 | 15 |
| Margins and ratios | ||||||||||
| Gross margin | 85.7% | 87.1% | 88.2% | 88.5% | 88.9% | 90.4% | 88.6% | 91.1% | 77.9% | 79.5% |
| Operating margin | −73.1% | −13.4% | 0.4% | 7.0% | 9.4% | 7.7% | −1.9% | 0.3% | −3.6% | −1.7% |
| Net margin | −73.9% | −13.8% | 0.4% | 6.9% | 22.4% | 9.5% | 0.6% | −8.3% | −11.1% | 5.3% |
| Free cash flow margin | −60.5% | −2.1% | 11.8% | 8.3% | 13.7% | 8.6% | 2.3% | 8.2% | 15.8% | 0.6% |
| Rule of 40 (growth + FCF margin) | −12.2% | 19.3% | 59.0% | 40.5% | 34.8% | 44.9% | 28.8% | 24.5% | −39.9% | 5.8% |
| Return on capital | −272.1% | — | — | — | — | — | — | — | — | — |
| Return on equity | −109.9% | −85.0% | — | 103.1% | 98.1% | 29.4% | 2.0% | −34.0% | −25.5% | 16.3% |
| Return on assets | −60.2% | −19.3% | 0.7% | 9.9% | 24.0% | 9.9% | 0.7% | −10.8% | −6.8% | 4.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |